Clinical trial
An Exploratory Open-Label Phase 2 Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder
NCT02226458 is registered in ClinicalTrials.gov with Edison Pharmaceuticals Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Open-Label Phase 2 Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder
- Lead sponsor
- Edison Pharmaceuticals Inc
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- October 31, 2014
- Completion date
- January 31, 2016
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.